Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avatrombopag DDI with Fluconazole, Itraconazole, or Rifampin
NCT02809768Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Apr 2016
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of avatrombopag in Thrombocytopenia (3 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Maximum Observed Concentration, Time to Maximum Concentration and 6 more. Started Apr 2016; status: completed.
02
Drugs
avatrombopag
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on NCT02809768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02809768.